Pablo Mora, FACE, MD

Pablo Mora, FACE, MD

Dallas Diabetes Research Center at Medical City Dallas (Texas)
Adjunct Associate Professor 
University of Texas Southwestern Medical Center at Dallas (Texas)

Related Videos

Q&A Session and Special “Hot Topics” Session “Hot Topics” in Diabetes: The Co-Chairs and Faculty Provide Up-to-the- Minute Analysis and Discussion of Top 10 FAQs Submitted by Diabetes, Endocrinology, Internal Medicine and Primary Care Physicians Video

Q&A Session and Special “Hot Topics” Session “Hot Topics” in Diabetes: The Co-Chairs and Faculty Provide Up-to-the- Minute Analysis and Discussion of Top 10 FAQs Submitted by Diabetes, Endocrinology, Internal Medicine and Primary Care Physicians

INTERACTIVE CASE MANAGEMENT SESSION and T2D CLINICAL DECISION TREE SIMULATION #1: COMPLEMENTARY ANTIGLYCEMIC COMBINATIONS Video

INTERACTIVE CASE MANAGEMENT SESSION and T2D CLINICAL DECISION TREE SIMULATION #1: COMPLEMENTARY ANTIGLYCEMIC COMBINATIONS

- ARS-Based, Interactive Session Focused on Patient with T2D Who is on Metformin and SGLT-2 Inhibitor plus a Basal Insulin and Still Has Suboptimal Control of Total HA1c Level in Combination with Evidence of PPG.

The Mandate and Necessity for Pan?Glycemic Control in T2D: Focus on Both FPG and Postprandial Hyperglycemia (PPG) to Improve HA1c Target Goal Attainment Video

The Mandate and Necessity for Pan?Glycemic Control in T2D: Focus on Both FPG and Postprandial Hyperglycemia (PPG) to Improve HA1c Target Goal Attainment

Q&A Session and Special “Hot Topics in T2D” Session “Hot Topics” in Type 2 Diabetes: Focus on Insulin-Based Management of T2D Video

Q&A Session and Special “Hot Topics in T2D” Session “Hot Topics” in Type 2 Diabetes: Focus on Insulin-Based Management of T2D

Diabetes Management Case Study #1 Video

Diabetes Management Case Study #1

Applying Updated ADA/EASD Guidelines to an Early-Onset Patient with T2D The Patient Who Has Not Achieved Ideal HA1c Levels after Metformin Alone and/or Metformin plus an SGLT-2 Inhibitor

Optimizing Glycemic Control While Mitigating Hypoglycemic Risk in Challenging Patients with T2D Video

Optimizing Glycemic Control While Mitigating Hypoglycemic Risk in Challenging Patients with T2D

Why, When, and in Whom Do ADA/EASD Guidelines Recommend “Physiologic” Basal Insulin for T2D? The Evidence for the Safety and Efficacy of Long-Acting Insulin

Interactive Q&A Session and Special “Hot Topics in T2D” Session Faculty Panel Video

Interactive Q&A Session and Special “Hot Topics in T2D” Session Faculty Panel

Interactive Q&A Session and Special “Hot Topics in T2D” Session.

Optimizing Glycemic Control While Mitigating Hypoglycemic Risk in T2D - Pablo F. Mora, MD, FACE, CDE Video

Optimizing Glycemic Control While Mitigating Hypoglycemic Risk in T2D - Pablo F. Mora, MD, FACE, CDE

Why, When, and in Whom Do ADA/EASD Guidelines Recommend “Physiologic” Basal Insulin for T2D? Expert- and Trial-Based Evidence for the Safety and Efficacy of Long-Acting Basal Insulin.

PHYSIOLOGIC LONG-ACTING BASAL INSULIN, INTERACTIVE (ARS) CASE MANGEMEMENT SESSION #1 - Pablo Mora, MD, MSc, FACE, CDE Video

PHYSIOLOGIC LONG-ACTING BASAL INSULIN, INTERACTIVE (ARS) CASE MANGEMEMENT SESSION #1 - Pablo Mora, MD, MSc, FACE, CDE

Applying Updated ADA/EASD Guidelines to a Patient with T2D Who Has Not Achieved Ideal HA1c Levels with Metformin plus an SGLT-2 Inhibitor and Who is at Moderate to Significant Risk for Hypoglycemia.